Female Stress Urinary Incontinence
Female stress urinary incontinence (SUI) results from urethral hypermobility, intrinsic sphincter deficiency (ISD), or both. Treatment selection is guided by incontinence severity, degree of hypermobility vs. ISD, prior pelvic surgery or radiation, mesh eligibility, and patient goals. Behavioral and conservative measures are always first-line; surgical intervention is reserved for patients who have failed or declined conservative management.
10 of 10 treatments
| Treatment | Category | Notes |
|---|---|---|
| Pelvic Floor Physical Therapy | Conservative | Canonical supervised PFPT/PFMT program for female SUI: strength, endurance, quick recruitment, coordination, and the Knack. First-line before surgery unless declined. Biofeedback or electrical stimulation can be added when the patient cannot isolate the correct muscles. |
| Incontinence Pessary | Conservative | Incontinence ring or dish pessary provides urethral support during increased abdominal pressure. Suitable for patients who prefer to avoid surgery or are poor surgical candidates. Requires fitting and ongoing pelvic floor follow-up. |
| Duloxetine | Pharmacological | Serotonin-norepinephrine reuptake inhibitor that increases urethral sphincter tone via pudendal motor neurons. Not FDA-approved for SUI in the United States; used in Europe and off-label. Modest efficacy (50% reduction in incontinence episodes); nausea limits tolerability in ~25% of patients. |
| Urethral Bulking Agents | Minimally Invasive | Periurethral or transurethral injection of bulking material (Bulkamid — PAHG; Macroplastique — silicone; Coaptite — calcium hydroxylapatite) to coapt the urethra. Best suited for ISD-predominant SUI in patients who are poor surgical candidates or have a fixed, scarred urethra. Durable continence at 12 months in 40–60%; repeat injections frequently needed. |
| Retropubic Mid-Urethral Sling (TVT) | Surgical | Tension-free vaginal tape placed at the mid-urethra via the retropubic space. Gold standard for hypermobility-predominant SUI. Cure rates 80–90% at 5 years; risk of bladder perforation (~5%), retropubic hematoma, and voiding dysfunction. Higher TVT-O efficacy in ISD compared with transobturator route. |
| Transobturator Mid-Urethral Sling (TOT / TVT-O) | Surgical | Polypropylene tape passed through the obturator foramen (outside-in TOT or inside-out TVT-O). Comparable cure rates to retropubic TVT for hypermobility SUI with lower risk of bladder injury and voiding dysfunction; higher rate of groin/thigh pain and potentially lower efficacy in ISD. |
| Single-Incision Mini-Sling | Surgical | Anchored mini-sling (Altis, Solyx) placed through a single vaginal incision without exit trocar passes. Non-inferior to full-length TOT for objective cure at 1 year in select trials; smaller footprint reduces groin pain. Less long-term data than standard MUS. |
| Autologous Fascial Pubovaginal Sling | Surgical | Rectus fascia or fascia lata sling placed at the bladder neck or proximal urethra with suprapubic fixation. Preferred over synthetic sling in mesh-contraindicated patients (prior erosion, urethral damage, radiation), ISD-predominant incontinence, and concomitant urethral reconstruction. Cure rates comparable to MUS; higher voiding dysfunction rates. |
| Burch Colposuspension | Surgical | Vaginal wall suspension to Cooper's ligament via open retropubic or laparoscopic approach. Historical gold standard; now typically reserved for patients undergoing concomitant abdominal/laparoscopic pelvic surgery. Cure rates 85–90% at 1 year, declining to 70% at 10 years; risk of de novo urgency and enterocele. |
| Artificial Urinary Sphincter (AUS) | Surgical | AMS 800 or ZSI 375 cuff placement around the bladder neck or proximal urethra. Reserved for severe ISD-predominant SUI not amenable to sling (fixed urethra, prior urethral reconstruction, radiation). Less commonly used in females than males but provides durable continence with appropriate patient selection. |